School of Pharmaceutical Sciences , Zhengzhou University , 100 Kexue Avenue , Zhengzhou 450001 , China.
Collaborative Innovation Center of New Drug Research and Safety Evaluation , Zhengzhou 450001 , Henan Province , China.
ACS Appl Mater Interfaces. 2018 Jul 5;10(26):21927-21938. doi: 10.1021/acsami.8b06998. Epub 2018 Jun 22.
Glucose-responsive insulin delivery systems, which can maintain a stable level of blood glucose, have been proposed as a promising method to treat diabetes. Such systems can reduce potential toxicity and enhance patient compliance compared to traditional therapies. Accordingly, we designed a mesoporous silica nanoparticle (MSN)-based glucose-sensitive and self-regulated drug release system to achieve the goal of long circulation and "touch switch" in vivo. In this system, carboxyphenylboronic acid (CPBA) was first modified on the surface of MSN using amidation reaction. Insulin (INS) was then loaded in the channels of MSN (CPBA-MSN/INS) through physical adsorption, and sodium alginate (SA) was introduced onto the surface of the CPBA-MSN/INS nanoparticles as the gatekeeper via amidation reaction (SA/CPBA-MSN/INS). We found the drug loading capacity of INS was 261 mg/g. In the normal range of blood glucose, INS was scarcely released due to the reversible covalent interaction between 1,2-diols of SA and CPBA. Within the high concentration of glucose, the boronate esters could be dissociated, which results in the mesoporous channels opening and the release of INS. In vivo experiments on diabetic mice showed SA/CPBA-MSN/INS sustained a normal blood glucose level for up to 12 h with a single dose. Moreover, the lipid metabolism disorder and organ damage of diabetic mice were alleviated after treatment with SA/CPBA-MSN/INS. Therefore, SA/CPBA-MSN/INS characterized by an "on-off" regulated drug release property and high biosafety shows promise for applications in diabetes treatment.
葡萄糖响应型胰岛素递药系统能够维持血糖的稳定水平,被认为是治疗糖尿病的一种很有前途的方法。与传统疗法相比,这种系统可以降低潜在的毒性并提高患者的顺应性。因此,我们设计了一种基于介孔硅纳米粒子(MSN)的葡萄糖敏感和自调节药物释放系统,以实现体内长循环和“触摸开关”的目标。在该系统中,首先通过酰胺反应将羧基苯硼酸(CPBA)修饰在 MSN 的表面。然后,胰岛素(INS)通过物理吸附被装载在 MSN 的通道中(CPBA-MSN/INS),并通过酰胺反应将海藻酸钠(SA)引入 CPBA-MSN/INS 纳米粒子的表面作为门控(SA/CPBA-MSN/INS)。我们发现 INS 的载药能力为 261mg/g。在正常血糖范围内,由于 SA 和 CPBA 之间 1,2-二醇的可逆共价相互作用,INS 几乎没有释放。在高浓度葡萄糖内,硼酸酯可以被解离,导致介孔通道打开并释放 INS。在糖尿病小鼠的体内实验中,单次给药后,SA/CPBA-MSN/INS 可持续将血糖水平维持在正常水平长达 12 小时。此外,SA/CPBA-MSN/INS 治疗后,糖尿病小鼠的脂质代谢紊乱和器官损伤得到缓解。因此,具有“开-关”调节药物释放特性和高生物安全性的 SA/CPBA-MSN/INS 有望应用于糖尿病治疗。